Alzheimer’s disease; executive function; longitudinal; memory; mild cognitive impairment; non-linear; practice effects; subjective cognitive decline; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental Health; General Neuroscience
Abstract :
[en] [en] BACKGROUND: Cognitive decline is a key outcome of clinical studies in Alzheimer's disease (AD).
OBJECTIVE: To determine effects of global amyloid load as well as hippocampus and basal forebrain volumes on longitudinal rates and practice effects from repeated testing of domain specific cognitive change in the AD spectrum, considering non-linear effects and heterogeneity across cohorts.
METHODS: We included 1,514 cases from three cohorts, ADNI, AIBL, and DELCODE, spanning the range from cognitively normal people to people with subjective cognitive decline and mild cognitive impairment (MCI). We used generalized Bayesian mixed effects analysis of linear and polynomial models of amyloid and volume effects in time. Robustness of effects across cohorts was determined using Bayesian random effects meta-analysis.
RESULTS: We found a consistent effect of amyloid and hippocampus volume, but not of basal forebrain volume, on rates of memory change across the three cohorts in the meta-analysis. Effects for amyloid and volumetric markers on executive function were more heterogeneous. We found practice effects in memory and executive performance in amyloid negative cognitively normal controls and MCI cases, but only to a smaller degree in amyloid positive controls and not at all in amyloid positive MCI cases.
CONCLUSIONS: We found heterogeneity between cohorts, particularly in effects on executive functions. Initial increases in cognitive performance in amyloid negative, but not in amyloid positive MCI cases and controls may reflect practice effects from repeated testing that are lost with higher levels of cerebral amyloid.
Disciplines :
Neurology
Author, co-author :
Teipel, Stefan J; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
Dyrba, Martin; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
Levin, Fedor; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
Altenstein, Slawek; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Berger, Moritz; Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany
Beyle, Aline; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg
Brosseron, Frederic; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg
Buerger, Katharina; German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany ; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
Burow, Lena; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
Dobisch, Laura; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Ewers, Michael; German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany ; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
Fliessbach, Klaus; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg ; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany
Frommann, Ingo; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg ; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany
Glanz, Wenzel; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Goerss, Doreen; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
Gref, Daria; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany
Hansen, Niels; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany
HENEKA, Michael ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB)
Incesoy, Enise I; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany ; Department for Psychiatry and Psychotherapy, University Clinic Magdeburg, Magdeburg, Germany pGerman Center for Neurodegenerative Diseases (DZNE), T¨ubingen, Germany
Janowitz, Daniel; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
Keles, Deniz; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany
Kilimann, Ingo; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany
Laske, Christoph; German Center for Neurodegenerative Diseases (DZNE), T¨ubingen, Germany ; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of T¨ubingen, T¨ubingen, Germany
Lohse, Andrea; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Munk, Matthias H; German Center for Neurodegenerative Diseases (DZNE), T¨ubingen, Germany ; Department of Psychiatry and Psychotherapy, University of T¨ubingen, T¨ubingen, Germany
Perneczky, Robert; German Center for Neurodegenerative Diseases (DZNE), Munich, Munich, Germany ; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany ; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany ; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK
Peters, Oliver; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany
Preis, Lukas; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
Priller, Josef; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany ; School of Medicine, Technical University of Munich, Department of Psychiatry and Psychotherapy, Munich, Germany ; University of Edinburgh and UK DRI, Edinburgh, UK
Rostamzadeh, Ayda; Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany
Roy, Nina; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg
Schmid, Matthias; Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany ; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg
Schneider, Anja; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg ; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany
Spottke, Annika; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg ; Department of Neurology, University of Bonn, Bonn, Germany
Spruth, Eike Jakob; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany
Wiltfang, Jens; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany ; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany ; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Düzel, Emrah; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
Jessen, Frank; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg ; Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany
Kleineidam, Luca; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany
Wagner, Michael; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg ; University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany
DELCODE study group and the Alzheimer’s Disease Neuroimaging Initiative
The work was supported by a grant to SJT within the CureDem funding of the Federal Ministry of Research (BMBF), grant number 01KX2130.The DELCODE study (Study-ID: BN012) was supported and conducted by the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE). The data samples were provided by the DELCODE study group. Details and participating sites can be found at www.dzne.de/en/research/studies/clinical-studies/delcode. The DELCODE study was supported in respect to the MR imaging by Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin; Center for Cognitive Neuroscience Berlin (CCNB) at Freie Universität Berlin; Bernstein Center for Computational Neuroscience (BCCN), Berlin; Core Facility MR-Research in Neurosciences, University Medical Center Goettingen; Institute for Clinical Radiology, Ludwig Maximilian University, Munich; Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center; and Magnetic Resonance research center, University Hospital Tuebingen. The work was supported by a grant to SJT within the CureDem funding of the Federal Ministry of Research (BMBF), grant number 01KX2130.
Teipel SJ, Cavedo E, Lista S, Habert MO, Potier MC, Grothe MJ, Epelbaum S, Sambati L, Gagliardi G, Toschi N, Greicius MD, Dubois B, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI) (2018) Effect of Alzheimer's disease risk and protective factors on cognitive trajectories in subjective memory complainers: An INSIGHT-preAD study. Alzheimers Dement 14, 1126-1136.
Machulda MM, Pankratz VS, Christianson TJ, Ivnik RJ, MielkeMM, RobertsRO, Knopman DS, BoeveBF, Petersen RC (2013) Practice effects and longitudinal cognitive change in normal aging vs. incident mild cognitive impairment and dementia in the Mayo Clinic Study of Aging. Clin Neuropsychol 27, 1247-1264.
Hassenstab J, Ruvolo D, Jasielec M, Xiong C, Grant E, Morris JC (2015) Absence of practice effects in preclinical Alzheimer's disease. Neuropsychology 29, 940-948.
Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, Maruff P (2017) Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: A meta-analysis. Alzheimers Dement (Amst) 6, 108-121.
Aksman LM, Scelsi MA, Marquand AF, Alexander DC, Ourselin S, Altmann A, for A (2019) Modeling longitudinal imaging biomarkers with parametric Bayesian multi-task learning. Hum Brain Mapp 40, 3982-4000.
Cespedes MI, Fripp J, McGree JM, Drovandi CC, Mengersen K, Doecke JD (2017) Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference. BMJ Open 7, e012174.
Dai T, Guo Y, Alzheimer's Disease Neuroimaging Initiative (2017) Predicting individual brain functional connectivity using a Bayesian hierarchical model. Neuroimage 147, 772-787.
Temp AGM, LutzMW, Trepel D, Tang Y,Wagenmakers EJ, Khachaturian AS, Teipel S (2021) How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease. Alzheimers Dement 17, 917-919.
Wagenmakers EJ, Marsman M, Jamil T, Ly A, Verhagen J, Love J, Selker R, Gronau QF, Smira M, Epskamp S, MatzkeD, Rouder JN, MoreyRD(2018) Bayesian inference for psychology. Part I: Theoretical advantages and practical ramifications. Psychon Bull Rev 25, 35-57.
Gigerenzer G, Krauss S, Vitouch O (2004) The null ritual: What you always wanted to know about significance testing but were afraid to ask. In The Sage Handbook of Quantitative Methodology for the Social Sciences, Kaplan D, ed. Sage, Thousand Oaks, CA, pp. 391-408
Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Joshi AD, Lu M, Grundman M, Mintun MA, Skovronsky DM, PontecorvoMJ; AV45-A11 Study Group; AV45-A11 Study Group (2014) Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry 19, 1044-1051.
Teipel S, Gustafson D, Ossenkoppele R, Hansson O, Babiloni C, Wagner M, Riedel-Heller S, Kilimann I, Tang Y (2022) Alzheimer's disease-standard of diagnosis, treatment, care, and prevention. J Nucl Med 63, 981-985.
Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology 91, e859-e866.
WeinerMW, Aisen PS, Jack CR, Jr., Jagust WJ,Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M, Alzheimer's Disease Neuroimaging Initiative (2010) The Alzheimer's disease neuroimaging initiative: Progress report and future plans. Alzheimers Dement 6, 202-211 e207.
Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K,VillemagneV,Woodward M, AmesD(2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21, 672-687.
Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, Fliessbach K, Franke C, Fuentes M, Heneka MT, Janowitz D, Kilimann I, Laske C, Menne F, Nestor P, Peters O, Priller J, Pross V, Ramirez A, Schneider A, Speck O, Spruth EJ, Teipel S, Vukovich R,Westerteicher C,Wiltfang J, Wolfsgruber S, Wagner M, Duzel E (2018) Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). Alzheimers Res Ther 10, 15.
Yoo HS, Jeon S, Cavedo E, Ko M, Yun M, Lee PH, Sohn YH, Grothe MJ, Teipel S, Hampel H, Evans AC, Ye BS (2022) Association of beta-amyloid and basal forebrain with cortical thickness and cognition in Alzheimer and Lewy body disease spectra. Neurology 98, e947-e957.
Teipel SJ, Cavedo E, Hampel H, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative, Alzheimer Precision Medicine Initiative (2018) Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with Alzheimer's disease treated with cholinesterase inhibitors. Front Neurol 9, 642.
Schmitz TW, Nathan Spreng R, Alzheimer's Disease Neuroimaging Initiative (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun 7, 13249.
Dore V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetelat G, Zhou L, Martins R, Ellis KA, Masters CL, Ames D, Salvado O, RoweCC(2013) Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease. JAMA Neurol 70, 903-911.
Stoub TR, Rogalski EJ, Leurgans S, Bennett DA, deToledo-Morrell L (2010) Rate of entorhinal and hippocampal atrophy in incipient and mild AD: Relation to memory function. Neurobiol Aging 31, 1089-1098.
Rover C (2020) Bayesian random-effects meta-analysis using the bayesmeta R package. J Stat Softw 93, 1-51.
Schindler SE, Jasielec MS,Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM (2017) Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Neurobiol Aging 56, 25-32.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the InternationalWorking Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M, Subjective Cognitive Decline Initiative Working Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10, 844-852.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, PhelpsCH(2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D, Alzheimer's Disease Neuroimaging Initiative (2012) Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6, 502-516.
Gibbons LE, CarleAC,Mackin RS, Harvey D, Mukherjee S, Insel P, Curtis SM, Mungas D, Crane PK (2012) A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 6, 517-527.
Albrecht MA, Szoeke C, Maruff P, Savage G, Lautenschlager NT, Ellis KA, Taddei K, Martins R, Masters CL, Ames D, Foster JK, AIBL Research Group (2015) Longitudinal cognitive decline in the AIBL cohort: The role of APOE epsilon4 status. Neuropsychologia 75, 411-419.
Arbuthnott K, Frank J (2000) Trail making test, part B as a measure of executive control: Validation using a setswitching paradigm. J Clin Exp Neuropsychol 22, 518-528.
Teipel SJ, Dyrba M, Ballarini T, Brosseron F, Bruno D, Buerger K, Cosma NC, Dechent P, Dobisch L, Duzel E, Ewers M, Fliessbach K, Haynes JD, Janowitz D, Kilimann I, LaskeC, Maier F, Metzger CD,MunkMH,Peters O, Pomara N, Preis L, Priller J, Ramirez A, RoyN, Scheffler K, Schneider A, Schott BH, SpottkeA, Spruth EJ,WagnerM,Wiltfang J, Jessen F, Heneka MT (2022) Association of cholinergic basal forebrain volume and functional connectivity with markers of inflammatory response in the Alzheimer's disease spectrum. J Alzheimers Dis 85, 1267-1282.
Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, Alzheimer's Disease Neuroimaging Initiative (2017) In vivo staging of regional amyloid deposition. Neurology 89, 2031-2038.
Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968-980.
Gonzalez-Escamilla G, Lange C, Teipel S, Buchert R, Grothe MJ, Alzheimer's Disease Neuroimaging I (2017) PETPVE12: An SPM toolbox for partial volume effects correction in brain PET-Application to amyloid imaging with AV45-PET. Neuroimage 147, 669-677.
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA (2015) The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11, 1-15.e11-14.
Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B, Leverenz J, Ironside JW, Schulz-Schaeffer WJ, Hoffmann A, Sabri O (2016) Cerebellar amyloid-beta plaques: How frequent are they, and do they influence 18F-Florbetaben SUV ratios? J Nucl Med 57, 1740-1745.
Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ,Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, AV45-A07 Study Group (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305, 275-283.
Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pon-tecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM (2011) Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68, 1404-1411.
Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, Pontecorvo MJ, Mintun MA, Devous MD, Sr. (2018) Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement 14, 1565-1571.
Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, Dore V, Villemagne VL, Buckley CJ (2018) Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res 8, 107.
Kurth F, Gaser C, Luders E (2015) A 12-step user guide for analyzing voxel-wise gray matter asymmetries in statistical parametric mapping (SPM). Nat Protoc 10, 293-304.
Kilimann I, Grothe M, Heinsen H, Alho EJ, Grinberg L, Amaro E, Jr., Dos Santos GA, da Silva RE, Mitchell AJ, Frisoni GB, Bokde AL, Fellgiebel A, Filippi M, Hampel H, Kloppel S, Teipel SJ (2014) Subregional basal forebrain atrophy in Alzheimer's disease: A multicenter study. J Alzheimers Dis 40, 687-700.
Frisoni GB, Jack CR Jr, Bocchetta M, Bauer C, Frederiksen KS, Liu Y, Preboske G, Swihart T, Blair M, Cavedo E, Grothe MJ, Lanfredi M, Martinez O, Nishikawa M, Portegies M, Stoub T,Ward C, Apostolova LG, Ganzola R,Wolf D, Barkhof F, Bartzokis G, DeCarli C, Csernansky JG, deToledo-Morrell L, Geerlings MI, Kaye J, Killiany RJ, Lehericy S, Matsuda H, O'Brien J, Silbert LC, Scheltens P, Soininen H, Teipel S, Waldemar G, Fellgiebel A, Barnes J, Firbank M, Gerritsen L, HennemanW, Malykhin N, Pruessner JC, Wang L, Watson C, Wolf H, deLeon M, Pantel J, Ferrari C, Bosco P, Pasqualetti P, Duchesne S, Duvernoy H, Boccardi M, EADC-ADNIWorking Group on The Harmonized Protocol for Manual Hippocampal Volumetry and for the Alzheimer's Disease Neuroimaging Initiative (2015) The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimers Dement 11, 111-125.
Wolf D, Bocchetta M, Preboske GM, Boccardi M, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative (2017) Reference standard space hippocampus labels according to theEADC-ADNIharmonized protocol: Utility in automated volumetry. Alzheimers Dement 13, 893-902.
Janelidze S, ZetterbergH, Mattsson N, Palmqvist S,Vanderstichele H, Lindberg O, vanWesten D, Stomrud E, Minthon L, Blennow K, Swedish BioFINDER study group, Hansson O (2016) CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3, 154-165.
Rhodes KM, Turner RM, Higgins JPT (2015) Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 68, 52-60.
Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS (2015) Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimers Dement (Amst) 1, 103-111.
Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ (2013) The effect of amyloid beta on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement 9, 687-698 e681.
Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, Stomrud E, Tideman P, Ohlsson T, Jogi J, Johnson K, Sperling R, Dore V, Masters CL, Rowe C, Visser D, van Berckel BNM, van der Flier WM, Baker S, Jagust WJ, Wiste HJ, Petersen RC, Jack CR, Jr., Hansson O (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med 28, 2381-2387.
Wilson RS, Yang J, Yu L, Leurgans SE, Capuano AW, Schneider JA, Bennett DA, Boyle PA (2019) Postmortem neurodegenerative markers and trajectories of decline in cognitive systems. Neurology 92, e831-e840.
Amaefule CO, Dyrba M,Wolfsgruber S, Polcher A, Schneider A, Fliessbach K, Spottke A, Meiberth D, Preis L, Peters O, Incesoy EI, Spruth EJ, Priller J, Altenstein S, Bartels C, Wiltfang J, Janowitz D, Burger K, Laske C, Munk M, Rudolph J, GlanzW, Dobisch L, Haynes JD, Dechent P, Ertl-Wagner B, Scheffler K, Kilimann I, Duzel E, Metzger CD, Wagner M, Jessen F, Teipel SJ (2021) Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. Neuroimage Clin 29, 102533.
Wolfsgruber S, Kleineidam L, Guski J, Polcher A, Frommann I, Roeske S, Spruth EJ, Franke C, Priller J, Kilimann I, Teipel S, Buerger K, Janowitz D, Laske C, Buchmann M, Peters O, Menne F, Fuentes Casan M, Wiltfang J, Bartels C, Duzel E, Metzger C, Glanz W, Thelen M, Spottke A, Ramirez A, Kofler B, Fliessbach K, Schneider A, Heneka MT, Brosseron F, Meiberth D, Jessen F, Wagner M, DELCODE Study Group (2020) Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology 95, e1134-e1143.
Bender AR, Ganguli A, Meiring M, Hampstead BM, Driver CC (2022) Dynamic modeling of practice effects across the healthy aging-Alzheimer's disease continuum. Front Aging Neurosci 14, 911559.
Howieson DB, Carlson NE, Moore MM, Wasserman D, Abendroth CD, Payne-Murphy J, Kaye JA (2008) Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc 14, 192-198.
Calamia M, Markon K, Tranel D (2012) Scoring higher the second time around: Meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol 26, 543-570.
Zheng B, Udeh-Momoh C, Watermeyer T, de Jager Loots CA, Ford JK, Robb CE, Giannakopoulou P, Ahmadi-Abhari S, Baker S, Novak GP, Price G, Middleton LT (2022) Practice effect of repeated cognitive tests among older adults: Associations with brain amyloid pathology and other influencing factors. Front Aging Neurosci 14, 909614.
Van Petten C (2004) Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: Review and meta-analysis. Neuropsychologia 42, 1394-1413.
Machulda MM, Hagen CE, Wiste HJ, Mielke MM, Knopman DS, Roberts RO, Vemuri P, Lowe VJ, Jack CR, Jr., Petersen RC (2017) Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. Clin Neuropsychol 31, 99-117.
Besson FL, La Joie R, Doeuvre L, Gaubert M, Mezenge F, Egret S, Landeau B, Barre L, Abbas A, Ibazizene M, de La Sayette V, Desgranges B, Eustache F, Chetelat G (2015) Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J Neurosci 35, 10402-10411.
Hillary FG, Medaglia JD (2020) What the replication crisis means for intervention science. Int J Psychophysiol 154, 3-5.
Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten JW, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, t Hoen PA, Hooft R,KuhnT,KokR,Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone SA, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B (2016) The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 3, 160018.
Sivula T, Magnusson M, Matamoros AA, Vehtari A (2020) Uncertainty in Bayesian Leave-One-Out Cross-Validation Based Model Comparison. arXiv: Methodology arXiv:2008.10296v3 [stat.ME] 17 Mar 2022.
